ASLAN Pharmaceuticals Limited (ASLN): Price and Financial Metrics


ASLAN Pharmaceuticals Limited (ASLN): $0.80

-0.02 (-2.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ASLN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ASLN Stock Price Chart Interactive Chart >

Price chart for ASLN

ASLN Price/Volume Stats

Current price $0.80 52-week high $1.11
Prev. close $0.82 52-week low $0.34
Day low $0.78 Volume 149,275
Day high $0.84 Avg. volume 219,726
50-day MA $0.58 Dividend yield N/A
200-day MA $0.56 Market Cap 55.80M

ASLAN Pharmaceuticals Limited (ASLN) Company Bio


ASLAN Pharmaceuticals Pte. Ltd., a biotechnology company, develops immuno-oncology agents and targeted therapies. It offers ASLAN001, a pan-HER inhibitor for solid tumours; and ASLAN002, a cMET inhibitor for solid tumours. The company also inlicenses preclinical and early clinical/development compounds and candidate drugs from pharmaceutical companies focusing on oncology, respiratory, and inflammation diseases; gets proof of concept (PoC) for the partnered compounds in Asia; and outlicenses PoC compounds back to partner for development and launch. It sells its products in Asia and internationally. ASLAN Pharmaceuticals Pte. Ltd. was founded in 2010 and is based in Singapore.


ASLN Latest News Stream


Event/Time News Detail
Loading, please wait...

ASLN Latest Social Stream


Loading social stream, please wait...

View Full ASLN Social Stream

Latest ASLN News From Around the Web

Below are the latest news stories about ASLAN PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate ASLN as an investment opportunity.

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday''s Mid-Day Session

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS ) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) climbed 162% to $0.4909 after the company announced it acquired Amerigen 7. Cryptyde, Inc. (NASDAQ: TYDE ) gained 108% to $0.4022. Geron Corporation (NASDAQ: GERN ) shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint. Shift Technologies, Inc. (NASDAQ: SFT ) rose 49% to $0.2350. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) jumped 42.4% to $0...

Benzinga | January 4, 2023

ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

SAN MATEO, Calif. and SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).

GlobeNewswire | January 3, 2023

Aslan, Thermo Fisher team up to make eblasakimab for clinical trials

Aslan Pharmaceuticals (ASLN) said it is collaborating with Thermo Fisher Scientific (TMO) to manufacture a high concentration formulation of eblasakimab for phase 3 trials.Aslan said…

Seeking Alpha | January 3, 2023

ASLAN, Thermo Fisher Join To Manufacture High Concentration Formulation Of Eblasakimab

SINGAPUR (dpa-AFX) - ASLAN Pharmaceuticals (ASLN) and Thermo Fisher Scientific Inc (TMO) announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical…

Finanz Nachrichten | January 3, 2023

Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

Yahoo | December 22, 2022

Read More 'ASLN' Stories Here

ASLN Price Returns

1-mo 21.25%
3-mo 62.11%
6-mo -5.67%
1-year -19.35%
3-year -62.44%
5-year N/A
YTD 122.22%
2022 -67.86%
2021 -38.80%
2020 -9.85%
2019 -43.61%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6491 seconds.